Buffer looks cheap in early development, but at commercial scale it can become one of the largest hidden costs in downstream chromatography, spanning raw materials, water, labor, tank space, and waste. See where buffer volumes really come from and how the right purification technology can reduce buffer use without giving up performance.

As biologics grow more complex, biologics purity standards keep climbing, and "clean enough" isn't what it used to be. This guide breaks down the four impurity classes driving today's standards and what strong downstream purification looks like when it's built for the molecules now defining the industry.

In biologics manufacturing, the timeline often slips downstream rather than upstream. This piece examines the most common downstream scale-up challenges, from reproducing steps at new scales to material variability and site-to-site differences, and the purification choices that make scale-up and tech transfer more predictable.

Selecting the right membrane chromatography solution can reduce costs, increase throughput, and simplify scale-up. But with biologic modalities ranging from mAbs to pDNA, viral vectors, and mRNA, the best fit depends on your molecule, your chemistry, and your process. A practical guide to choosing well from the start.

The Purexa™ Process 50 NAEX 3μm membrane chromatography device is now available for sale for use in commercial manufacturing.

As biologics grow larger and more complex — from plasmid DNA and viral vectors to mRNA and monoclonal antibodies — traditional resin columns are falling behind. Membrane chromatography replaces slow, diffusion-based binding with rapid convective flow, cutting cycle times from hours to minutes while simplifying scale-up and supply chains. It's fast becoming the purification platform of choice for next-generation therapies.

It All Begins Here

Discover why traditional resin chromatography is falling short for advanced biologics purification. As the biopharmaceutical industry evolves, membrane chromatography offers faster cycle times, better scalability, and lower costs — with the market projected to reach $959.42M by 2032

As mRNA, saRNA, and plasmid DNA therapies move from breakthrough to broad clinical adoption, traditional resin and monolith chromatography are hitting their limits — struggling with size, shear sensitivity, and throughput. Next-generation membrane chromatography offers a faster, gentler, more scalable path forward for nucleic acid purification.